医药股普遍逆市造好 信达生物涨逾9% 惟国药及康希诺跌4%-6.6%
恒指今早高开29点,回升至26,436无以为继,掉头曾倒跌261点,低见26,127喘定,现造26,259,续吐130点或0.5%;国指跌0.3%,报10,411。
不过,医药相关股今早普遍逆市造好,上周五指宫颈癌联合疗法二期临床研究完成首例患者给药的信达生物(01801.HK)升破50天线(58.21元),最高见61.9元,现造61.4元,回升9.2%。
蓝筹石药(01093.HK)及中生制药(01177.HK)逆市连续第二天反弹,两者股价均重越10天线(7.52元及6.81元),最高见7.61元及7.08元,现造7.57元及7.01元,续弹3.8%及3.7%。同为蓝筹药明生物(02269.HK)低见77.7元获承接,掉头高见81.25元,现造80.9元,回升3.5%。药明康德(02359.HK)高见132.6元,现造132.2元,续升3.1%。
微创医疗(00853.HK)续升5.1%报39.25元;君实生物(01877.HK)续升2.3%报45.25元。复星医药(02196.HK)反覆三连升,报36.6元,反覆续升0.8%。联邦制药(03933.HK)重越10天线(5.78元),最高见5.88元,现造5.81元,回升2.5%。威高股份(01066.HK)反覆重越10天线(14.45元),现造14.62元,反覆续升1.8%。
相反,国药(01099.HK)股价失守50天及百天线(18.29元及18.4元),最低见18.12元,现造18.16元,续跌4%。早前遭基金减持的康希诺生物(06185.HK)三连跌,最低见152.5元,现造157元,续跌6.6%。
据《中国证券报》报道,内地第四批药品国家集采拉开序幕,部分公司因竞品纳指集采,火速公告预警提示降价风险。报道引述一位药企负责人表示,较为关注高端仿制药降价幅度,这对公司未来产品布局至关重要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.